buspirone has been researched along with Chronic Disease in 16 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess effects of a semi-acute administration of buspirone in comparison to a placebo on cognitive function and negative symptoms in patients with schizophrenia and schizoaffective disorder." | 9.14 | Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. ( Maruff, P; Norman, TR; Olver, JS; Piskulić, D, 2009) |
| "The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia." | 9.14 | A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. ( Akhondzadeh, S; Farnaghi, F; Ghaleiha, A; Hajiazim, M; Noorbala, AA, 2010) |
| "To assess effects of a semi-acute administration of buspirone in comparison to a placebo on cognitive function and negative symptoms in patients with schizophrenia and schizoaffective disorder." | 5.14 | Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. ( Maruff, P; Norman, TR; Olver, JS; Piskulić, D, 2009) |
| "The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia." | 5.14 | A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. ( Akhondzadeh, S; Farnaghi, F; Ghaleiha, A; Hajiazim, M; Noorbala, AA, 2010) |
| "This report presents results from an international multicenter trial of the safety of buspirone in the treatment of anxiety disorders for periods up to one year, if needed; 424 patients were treated for six months, and 264 patients completed a full year of treatment." | 5.06 | Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. ( Rakel, RE, 1990) |
| "Twelve volunteers with a complaint of chronic insomnia participated in a placebo-controlled, double-blind, crossover study of the effects of buspirone t." | 5.05 | Buspirone: an anxiolytic without sedative effect. ( Bliwise, NG; Cohen, SA; Dement, WC; Seidel, WF, 1985) |
| "Tricyclic antidepressants are modestly effective in reducing chronic tension-type headache and are superior to buspirone." | 4.95 | Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis. ( Bernstein, R; Jackson, JL; Kay, C; Mancuso, JM; Nickoloff, S, 2017) |
| "Buspirone is an antianxiety compound that has been extensively evaluated in clinical trials: it has proved superior to placebo and comparable to diazepam in the treatment of patients with generalized anxiety disorder." | 2.66 | A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. ( Lader, M; Olajide, D, 1987) |
| "Anxiety disorders are chronic illnesses requiring long-term treatment." | 2.38 | Chronic anxiety: deciding the length of treatment. ( Gorman, JM; Papp, LA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jackson, JL | 1 |
| Mancuso, JM | 1 |
| Nickoloff, S | 1 |
| Bernstein, R | 1 |
| Kay, C | 1 |
| Currow, D | 1 |
| Johnson, M | 1 |
| White, P | 1 |
| Abernethy, A | 1 |
| Pollack, MH | 1 |
| Piskulić, D | 1 |
| Olver, JS | 1 |
| Maruff, P | 1 |
| Norman, TR | 1 |
| Ghaleiha, A | 1 |
| Noorbala, AA | 1 |
| Farnaghi, F | 1 |
| Hajiazim, M | 1 |
| Akhondzadeh, S | 1 |
| Olsen, AS | 1 |
| Sozda, CN | 1 |
| Cheng, JP | 1 |
| Hoffman, AN | 1 |
| Kline, AE | 1 |
| Schuckit, MA | 1 |
| Esteban, S | 1 |
| Moranta, D | 1 |
| Sastre-Coll, A | 1 |
| Miralles, A | 1 |
| García-Sevilla, JA | 1 |
| Gorman, JM | 1 |
| Papp, LA | 1 |
| Rickels, K | 2 |
| Schweizer, E | 1 |
| Rakel, RE | 1 |
| Sovner, R | 1 |
| Parnell-Sovner, N | 1 |
| Seidel, WF | 1 |
| Cohen, SA | 1 |
| Bliwise, NG | 1 |
| Dement, WC | 1 |
| Olajide, D | 1 |
| Lader, M | 1 |
5 reviews available for buspirone and Chronic Disease
| Article | Year |
|---|---|
Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Buspirone; Chronic Disease; Humans; Randomi | 2017 |
Refractory generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiet | 2009 |
Chronic anxiety: deciding the length of treatment.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Chronic Disease; Drug Administra | 1990 |
The clinical course and long-term management of generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Chronic Disease; Follow-Up Studi | 1990 |
Antianxiety therapy: potential value of long-term treatment.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Chronic Disease; Counseling; Hum | 1987 |
5 trials available for buspirone and Chronic Disease
| Article | Year |
|---|---|
Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Buspirone; Chronic Disease; Cognition Disorders; | 2009 |
A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Buspirone; Chronic Disease; Double-Blind Method; Drug Therapy, Combinat | 2010 |
Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Buspirone; Chronic Disease; Drug Administration Schedule | 1990 |
Buspirone: an anxiolytic without sedative effect.
Topics: Adult; Anti-Anxiety Agents; Buspirone; Chronic Disease; Clinical Trials as Topic; Double-Blind Metho | 1985 |
A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Chronic Disease; Clinical Trials as Topic; | 1987 |
6 other studies available for buspirone and Chronic Disease
| Article | Year |
|---|---|
Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference.
Topics: Anti-Anxiety Agents; Benzodiazepines; Buspirone; Chronic Disease; Dyspnea; Evidence-Based Medicine; | 2013 |
Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone.
Topics: Animals; Brain Injuries; Buspirone; Chronic Disease; Cognition Disorders; Disease Models, Animal; Dr | 2012 |
Anxiety treatment. A commonsense approach.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Dis | 1984 |
Ongoing needs in depression. Symposium highlights from the World Congress of Psychiatry held in August 1996 in Madrid, Spain.
Topics: Antidepressive Agents; Buspirone; Chronic Disease; Combined Modality Therapy; Depressive Disorder; E | 1996 |
Withdrawal from chronic ethanol increases the sensitivity of presynaptic 5-HT(1A) receptors modulating serotonin and dopamine synthesis in rat brain in vivo.
Topics: 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain; Buspirone; Cerebral Cor | 2002 |
Use of buspirone in the treatment of schizophrenia.
Topics: Adolescent; Buspirone; Chronic Disease; Female; Humans; Schizophrenia; Schizophrenic Psychology | 1989 |